Genesis Biopharma (GNBP) Expands Focus to Develop Melanoma Treatment

QualityStocks would like to highlight Genesis Biopharma, Inc.(OTCBB: GNBP), a development-stage biotechnology company engaged in the development of targeted cancer therapies.

In the company’s news yesterday,

Genesis Biopharma announced it is expanding its clinical focus to include an autologous cell therapy product candidate Contego™ as treatment of stage IV metastatic melanoma.

The company noted that the product name “Contego” is well fitting of the treatment’s designated application – a Latin term meaning to shield or to protect. Genesis Biopharma will develop Contego as a ready-to-infuse autologous cell therapy product that contains tumor infiltrating lymphocytes (TILs) taken from a patient’s metastatic melanoma tumors.

Genesis Biopharma explained that after resection of the patient’s tumor, TILs are isolated from the resected tumor and are then expanded in vitro to several hundred million cells. The expanded TILs are then infused into the patient, where they are designed to attack melanoma tumors throughout the patient’s body.

“Our intention is to move expeditiously to develop Contego for the treatment of metastatic melanoma,” Anthony J. Cataldo., chairman and CEO of Genesis Biopharma stated in the press release. “With the help of our Scientific and Medical Advisory Board (SMAB), we are hopeful Contego will successfully advance through clinical development and the regulatory process, and become available as a therapeutic option for the estimated 20,000 patients worldwide with stage IV metastatic melanoma.”

Cataldo, along with other members of the company’s SMAB, recently met in Chicago for the American Society of Clinical Oncology (ASCO) symposia to review results from similar therapeutic approaches conducted by some of the nation’s leading cancer care centers, as well as to plan for the clinical development of Contego.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.